AION Laboratories, an AI-enabled drug discovery cooperation between multinational pharma and IT businesses with headquarters in Israel, has announced the establishment of DenovAI, its second company.
DenovAI will provide a computational biophysics platform with AI that can find possible antibodies against particular epitopes (the part of an antigen molecule recognized by the immune system to which an antibody attaches itself). The platform, according to the vendor, would create brand-new antibodies before recommending which potential medication candidates are most likely to be successful.
Pharma behemoths AstraZeneca, Merck, Pfizer, and Teva, as well as venture capital firm Israel Biotech Fund, business partner Amazon Web Services, and German independent research organization Bio Med X, comprise AION Laboratories, which was established as the result of a government tender.
AION Laboratories will give DenovAI funding and pharmaceutical data for machine learning research and model training.
“Therapeutic antibodies have made significant strides, but the process of creating new medications is extraordinarily slow, exorbitantly expensive, and ineffective. We are working to create a cutting-edge solution that will revolutionize the industry and reduce discovery times from months to days with the help of AION Labs and its partners. Moreover, which could greatly increase the number of disorders for which antibody therapy is effective “DenovAI’s founder and CEO, Dr. Kashif Sadiq, stated in a release.
THE GENERAL TEND
AION Labs revealed the name of its first firm, OMEC, last year.
AI, which intends to develop an AI-enabled computational platform to assist researchers in evaluating a drug candidate’s suitability for a clinical trial, identifying hidden safety risks, and suggesting experiments to fill any gaps that may be found.
“What we’re trying to do at AION Labs in general… is creating great independent-growth AI-based startups for the biotech field so we can help scientists and researchers — not to replace them, but to really empower them by bringing new technological capability so that they can optimize the entire process of drug discovery and development,” Mati Gil, CEO of AION Labs, said in September to MobiHealthNews.
Insilico Medical, a platform for drug research, and Healx, a UK-based health tech company, are two further businesses using AI technologies for drug development. Healx employs AI to speed up drug discovery and treatments for uncommon disorders.
